WebSify
Follow us on
Mail
Print

Himalaya Drugs recalls skin care cream in US

Source : BUSINESS_STANDARD
Last Updated: Mon, Jan 02, 2012 19:34 hrs

The US arm of Himalaya Drugs, leading ayurvedic drug maker, has recalled two batches of Organique, its skin care cream brand, after fungus and bacteria were found in bottles in the American market.

According to a statement from the US Food & Drug Administration, Himalaya USA is conducting a voluntary recall of two batches of Organique (nourishing night cream) with immediate effect. The product was distributed nationwide in the US and in Canada.

"The bacteria staphylococcus aureus and fungus were found in samples of the nourishing night cream batches and were traced to the bottle’s pump components, which were supplied by a third-party manufacturer. These microbes are likely to enter the human body, if introduced to broken skin. As there is no way to determine if all pumps (used) contained these microbes, Himalaya USA is recalling the entire batch," the statement said.

Details of financial loss following the recall are not known. Without elaborating, a Himalaya Drug spokesperson said, "We won’t be able to disclose any financials, since we are a privately held company."

The Bangalore-based firm has a turnover of Rs 1,000 crore. Its key verticals — pharma and fast moving consumer goods — contribute 60 and 40 per cent, respectively, to overall revenues.

Last March, in a similar move, Glenmark made a voluntary recall of a skin ointment from the US after the drug exceeded the permissible impurity level.

In August, domestic drug major Dr Reddy’s Labs recalled certain batches of cholesterol lowering drug simvastatin tablets in the US due to complaints that the tablets smelled 'musty or moldy'. In December 2010, Dr Reddy’s had recalled 25,896 bottles of Simvastatin due to chemical contamination.

In August, Lupin had recalled one batch of Losartan Potassium t, used in treating high blood pressure, from the US market, for exceeding permissible impurity level.



blog comments powered by Disqus
most popular on facebook
talking point on sify finance